Titre :

Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - a retrospective study by the ebmt chronic malignancies working party

Auteur(s) :

Radujkovic, Aleksandar [Auteur]
Dietrich, Sascha [Auteur]
Blok, Henric-Jan [Auteur]
Nagler, Arnon [Auteur]
Ayuk, Francis [Auteur]
Finke, Jurgen [Auteur]
Tischer, Johanna [Auteur]
Mayer, Jiri [Auteur]
Koc, Yener [Auteur]
Sora, Federica [Auteur]
Passweg, Jakob [Auteur]
Byrne, Jenny L. [Auteur]
Jindra, Pavel [Auteur]
Veelken, Hendrik [Auteur]
Socie, Gerard [Auteur]
Maertens, Johan [Auteur]
Schaap, Nicolaas [Auteur]
Stadler, Michael [Auteur]
Itala-Remes, Maija [Auteur]
Tholouli, Eleni [Auteur]
Arat, Mutlu [Auteur]
Rocha, Vanderson [Auteur]
Ljungman, Per [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Kroger, Nicolaus [Auteur]
Chalandon, Yves [Auteur]

Titre de la revue :

Biology of Blood and Marrow Transplantation

Nom court de la revue :

Biol. Blood Marrow Transplant.

Numéro :

25

Pagination :

2008-2016

Date de publication :

2019-10

ISSN :

1523-6536

Mot(s)-clé(s) en anglais :

Blast crisis
transplantation
Allogeneic stem cell
Chronic myeloid leukemia
Tyrosine kinase inhibitor
Outcome

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. ...
Lire la suite >The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P = .010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P = .017). For patients with BC in remission at transplant, advanced age (≥45 years), lower performance status (≤80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:28:01Z
2024-01-31T13:42:55Z